The androgen receptor (AR) is an emerging prognostic marker and therapeutic target in breast cancer. AR is expressed in 60-80% of breast cancers, with higher prevalence among estrogen receptor-positive (ER+) tumors. Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic studies. However, whether AR expression modifies the efficacy of selective ER modulators or aromatase inhibitors for ER+ cancers remains unclear.
Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer : results from the Breast International Group Trial 1-98 / K.H. Kensler, M.M. Regan, Y.J. Heng, G.M. Baker, M.E. Pyle, S.J. Schnitt, A. Hazra, R. Kammler, B. Thürlimann, M. Colleoni, G. Viale, M. Brown, R.M. Tamimi. - In: BREAST CANCER RESEARCH. - ISSN 1465-542X. - 21:1(2019 Feb 22), pp. 30.1-30.11.
Titolo: | Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer : results from the Breast International Group Trial 1-98 |
Autori: | |
Parole Chiave: | Androgen receptor; BIG 1–98; Breast cancer; Letrozole; Tamoxifen |
Settore Scientifico Disciplinare: | Settore MED/08 - Anatomia Patologica |
Data di pubblicazione: | 22-feb-2019 |
Rivista: | |
Tipologia: | Article (author) |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1186/s13058-019-1118-z |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
AR in BIG1_98.pdf | Publisher's version/PDF | Open Access Visualizza/Apri |